Gold Fields Limited (GFI)
NYSE: GFI · Real-Time Price · USD
31.29
+0.16 (0.51%)
At close: Aug 8, 2025, 4:00 PM
31.35
+0.06 (0.19%)
After-hours: Aug 8, 2025, 7:59 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $24.03, which forecasts a -23.20% decrease in the stock price over the next year. The lowest target is $18.8 and the highest is $33.3.
Price Target: $24.03 (-23.20%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +6.42% | Jul 28, 2025 |
| HSBC | HSBC | Strong Buy → Hold Downgrades $21 | Strong Buy → Hold | Downgrades | $21 | -32.89% | Apr 17, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | -26.49% | Apr 14, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $18 → $20 | Hold | Maintains | $18 → $20 | -36.08% | Feb 25, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $17 → $19 | Hold | Maintains | $17 → $19 | -39.92% | Jan 15, 2025 |
Financial Forecast
Revenue This Year
7.76B
from 5.20B
Increased by 49.24%
Revenue Next Year
9.08B
from 7.76B
Increased by 17.00%
EPS This Year
2.69
from 1.38
Increased by 95.26%
EPS Next Year
3.11
from 2.69
Increased by 15.65%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 8.6B | 10.3B | 9.7B |
| Avg | 7.8B | 9.1B | 8.1B |
| Low | 6.0B | 8.0B | 6.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 65.5% | 33.1% | 6.9% |
| Avg | 49.2% | 17.0% | -11.2% |
| Low | 15.6% | 3.0% | -29.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.35 | 4.25 | 3.86 |
| Avg | 2.69 | 3.11 | 2.62 |
| Low | 1.89 | 1.71 | 1.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 142.8% | 57.8% | 23.9% |
| Avg | 95.3% | 15.7% | -15.8% |
| Low | 37.2% | -36.6% | -45.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.